Observational studyAbdominal radiology (New York)2025
Low-osmolar contrast tagging in minimally cathartic CT colonography for colorectal cancer screening: an observational study.
Observational study in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAdequate bowel preparation and tagging are critical in optimizing CTC performance. Iohexol has a higher safety profile than other available tagging agents. This study aims to determine if iohexol serves as an adequate fluid and stool tagging agent in conjunction with minimally cathartic bowel preparation.
methodsIn this prospective observational study, 50 participants ingested 50 mL of oral iohexol for tagging and 10 oz magnesium citrate for bowel preparation prior to CTC. Written informed consent was obtained. CTC was performed in all participants in at least two of the standard four positions (supine, prone, right decubitus, and left decubitus). Two board-certified abdominal radiologists independently scored the 6 colonic segments of participants who underwent successful CTC. The amount of residual fluid and solid stool, attenuation of tagged fluid, and efficacy of fluid and stool tagging were recorded in each segment. Statistical analyses were performed with R-4.4.0.
results47 participants (mean age 66.39 ± 8.65 years; 39 female) underwent successful CTC. Of 1252 total colonic segments, 14.8% had no residual fluid and 59.5% had < 25% residual fluid. 73.6% of segments with residual fluid demonstrated good tagging. The mean fluid tagging efficacy ratio for all segments was 0.737 (95% CI: 0.700-0.775) with mean attenuation of 467 HU. Fluid tagging efficacy decreased from the cecum (0.934) to rectum (0.493). 92.8% of segments had no residual solid stool. Of the 7.2% of segments containing solid stool, 4.7% of segments had submerged stool ≤ 5 mm, 0.8% had 1-3 pieces of retained stool between 6 and 9 mm, and 1.8% had > 3 pieces 6-9 mm or single pieces > 1 cm.
conclusionLow-volume (50 mL) iohexol is an effective fluid and fecal tagging agent for CTC with a minimally cathartic bowel preparation. This provides an easy option to label residual material and cleanse the bowel for patients undergoing CTC.
Indexed as
Identifiers
40372429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.